Image_4_Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.TIF
Objective: This study aimed to evaluate the potential association between uric acid (UA) lowering and cardiovascular risk reduction among UA-lowering therapies in adults.
Methods: A systematic search for randomized controlled trials (RCTs) was conducted according to the protocol pre-registered in PROSPERO (No. CRD42020199259). We search for RCTs in PubMed, Embase, Web of Science, the Cochrane Library, and ClinicalTrials.gov up to July 1, 2020. A meta-analysis was performed using a fixed- or random-effects model.
Results: In total, 30 studies involving 18,585 hyperuricaemic patients were included. Xanthine oxidase inhibitor (XOI) therapy produced a 6.0% reduction in relative risk (RR) for major adverse cardiovascular events (MACEs). The use of febuxostat was associated with a higher risk of cardiovascular events (CVEs) (RR: 1.09, 95% CI 0.998–1.19, I2 = 0.0%), but the difference was not statistically significant. Allopurinol treatment was associated with a lower CVE risk (RR: 0.61, 95% CI 0.46–0.80, I2 = 21.0%). Among the UA-lowering therapies, the drug treatments were associated with all-cause mortality (RR: 1.20, 95% CI 1.02–1.41, I2 = 0.0%). The subgroup with a UA endpoint <7 mg/dl was not associated with a higher CVE risk (RR: 0.57, 95% CI 0.35–0.92, I2 = 0.0%), and in the subgroup with a UA endpoint <5 mg/dl group, a lower risk of CVEs was not observed (RR: 0.99, 95% CI 0.69–1.44, I2 = 0.0%).
Conclusions: UA reduction caused by XOIs reduced the incidence of MACEs. UA-lowering medicines were associated with changes in all-cause mortality but not cardiovascular outcomes. The lower UA endpoint was not associated with reduced cardiovascular risk.
History
References
- https://doi.org//10.1056/NEJMra0800885
- https://doi.org//10.1681/ASN.2014070660
- https://doi.org//10.1001/jama.283.18.2404
- https://doi.org//10.1053/j.ajkd.2003.12.023
- https://doi.org//10.1111/j.1523-1755.2004.938_8.x
- https://doi.org//10.1097/HJH.0000000000000701
- https://doi.org//10.1002/art.40807
- https://doi.org//10.1177/1759720X16646703
- https://doi.org//10.1002/art.40159
- https://doi.org//10.1016/j.jacc.2007.10.034
- https://doi.org//10.1136/bmj.308.6943.1540
- https://doi.org//10.1097/HJH.0000000000002600
- https://doi.org//10.1159/000512178
- https://doi.org//10.1002/acr2.11047
- https://doi.org//10.1016/j.cca.2018.05.046
- https://doi.org//10.1371/journal.pone.0078206
- https://doi.org//10.1038/srep19520
- https://doi.org//10.2215/CJN.01580210
- https://doi.org//10.1056/NEJMoa1710895
- https://doi.org//10.1136/annrheumdis-2012-201795
- https://doi.org//10.1161/JAHA.117.007523
- https://doi.org//10.1007/s40292-020-00368-z
- https://doi.org//10.1161/HYPERTENSIONAHA.119.13643
- https://doi.org//10.1002/art.39840
- https://doi.org//10.1136/annrheumdis-2016-209213
- https://doi.org//10.1093/rheumatology/kex350
- https://doi.org//10.2174/138161205774913255
- https://doi.org//10.1093/eurheartj/ehz199
- https://doi.org//10.1038/srep33082